MX2021007475A - Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. - Google Patents
Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.Info
- Publication number
- MX2021007475A MX2021007475A MX2021007475A MX2021007475A MX2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A MX 2021007475 A MX2021007475 A MX 2021007475A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- piperidine
- compounds
- aminophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782281P | 2018-12-19 | 2018-12-19 | |
| US201962879927P | 2019-07-29 | 2019-07-29 | |
| PCT/US2019/067090 WO2020132016A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007475A true MX2021007475A (es) | 2021-08-05 |
Family
ID=71099150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007475A MX2021007475A (es) | 2018-12-19 | 2019-12-18 | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11325889B2 (https=) |
| EP (1) | EP3897635A4 (https=) |
| JP (1) | JP7492962B2 (https=) |
| KR (1) | KR102864064B1 (https=) |
| CN (1) | CN113473987B (https=) |
| AU (1) | AU2019404022A1 (https=) |
| BR (1) | BR112021012186A2 (https=) |
| CA (1) | CA3124101A1 (https=) |
| IL (1) | IL284187A (https=) |
| MX (1) | MX2021007475A (https=) |
| SG (1) | SG11202106506WA (https=) |
| TW (1) | TW202039434A (https=) |
| WO (1) | WO2020132016A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3897636T3 (pl) | 2018-12-19 | 2025-04-28 | Celgene Corporation | Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| PE20231746A1 (es) | 2020-06-24 | 2023-11-06 | Celgene Corp | Compuestos de union a cereblon, composiciones de estos y metodos de tratamiento con estos |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| JP2024543129A (ja) | 2021-11-25 | 2024-11-19 | 江蘇恒瑞医薬股▲ふん▼有限公司 | アンドロゲン受容体タンパク質の標的分解のためのキメラ化合物、その調製方法及びその医薬的使用 |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| TW200621723A (en) | 2004-09-09 | 2006-07-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivative and use thereof |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| DK2683694T3 (en) | 2011-03-10 | 2016-07-18 | Suzhou Kintor Pharmaceuticals Inc | ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| RS61242B1 (sr) | 2012-09-04 | 2021-01-29 | Shanghai hengrui pharmaceutical co ltd | Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US10730870B2 (en) | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017011371A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3481394A1 (en) | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US10925868B2 (en) | 2016-11-10 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| CA3042301A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| DK3524603T3 (da) | 2016-12-19 | 2022-07-04 | Abbisko Therapeutics Co Ltd | Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf |
| BR112019015484A2 (pt) * | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| ES2959954T3 (es) | 2017-11-28 | 2024-02-29 | Aarti Pharmalabs Ltd | Proceso para la preparación de enzalutamida utilizando un nuevo intermedio |
| CN111163638B (zh) | 2017-12-05 | 2023-07-25 | 美国陶氏益农公司 | 杀有害生物组合物和方法 |
| CA3101227A1 (en) | 2018-05-30 | 2019-12-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| PL3897636T3 (pl) | 2018-12-19 | 2025-04-28 | Celgene Corporation | Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi |
-
2019
- 2019-12-18 US US16/719,217 patent/US11325889B2/en active Active
- 2019-12-18 TW TW108146432A patent/TW202039434A/zh unknown
- 2019-12-18 BR BR112021012186-2A patent/BR112021012186A2/pt not_active Application Discontinuation
- 2019-12-18 MX MX2021007475A patent/MX2021007475A/es unknown
- 2019-12-18 JP JP2021535546A patent/JP7492962B2/ja active Active
- 2019-12-18 CA CA3124101A patent/CA3124101A1/en active Pending
- 2019-12-18 AU AU2019404022A patent/AU2019404022A1/en not_active Abandoned
- 2019-12-18 KR KR1020217022417A patent/KR102864064B1/ko active Active
- 2019-12-18 SG SG11202106506WA patent/SG11202106506WA/en unknown
- 2019-12-18 EP EP19899239.8A patent/EP3897635A4/en active Pending
- 2019-12-18 WO PCT/US2019/067090 patent/WO2020132016A1/en not_active Ceased
- 2019-12-18 CN CN201980092186.9A patent/CN113473987B/zh active Active
-
2021
- 2021-06-20 IL IL284187A patent/IL284187A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202106506WA (en) | 2021-07-29 |
| US20200199074A1 (en) | 2020-06-25 |
| KR102864064B1 (ko) | 2025-09-24 |
| JP7492962B2 (ja) | 2024-05-30 |
| JP2022514347A (ja) | 2022-02-10 |
| EP3897635A1 (en) | 2021-10-27 |
| CN113473987B (zh) | 2024-09-03 |
| US11325889B2 (en) | 2022-05-10 |
| EP3897635A4 (en) | 2022-08-31 |
| CA3124101A1 (en) | 2020-06-25 |
| AU2019404022A1 (en) | 2021-07-08 |
| CN113473987A (zh) | 2021-10-01 |
| TW202039434A (zh) | 2020-11-01 |
| KR20210118828A (ko) | 2021-10-01 |
| IL284187A (en) | 2021-08-31 |
| WO2020132016A1 (en) | 2020-06-25 |
| BR112021012186A2 (pt) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205718A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| MX2021007475A (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. | |
| SA522441857B1 (ar) | مركبات ربط سيريبلون، توليفات منها، وطرق للمعالجة باستخدامها | |
| MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| PH12021500013A1 (en) | New heterocyclic compounds as monoacylgylcerol lipase inhibitors | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| PH12018501413A1 (en) | Substituted thiohydantoin derivatives as androgen receptor antagonists | |
| MY206796A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| MX387736B (es) | Derivados de fenoximetilo. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MY188114A (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| EA201890256A1 (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
| PH12021553249A1 (en) | New heterocyclic compounds | |
| PH12019502277A1 (en) | Crystalline forms of (s)-afoxolaner | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| DK1480627T3 (da) | Fremgangsmåder til mindskelse af angiogenese | |
| MX2023014984A (es) | Anticuerpos anti-csp. | |
| EA202192237A1 (ru) | Кристаллические формы ингибитора jak2 | |
| EA202191712A1 (ru) | Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью | |
| EA202191713A1 (ru) | Замещенные соединения 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью | |
| EA200700041A1 (ru) | Способ получения 3-(4-пиперидинил)-2,3,4,5-тетрагидро-1,3-бензодиазепин-2(1н)-она |